Apellis Pharmaceuticals, Inc. APLS
We take great care to ensure that the data presented and summarized in this overview for Apellis Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding APLS
View all-
Avoro Capital Advisors LLC New York, NY12.2MShares$347 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$338 Million17.73% of portfolio
-
Wellington Management Group LLP Boston, MA11.8MShares$335 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$285 Million0.01% of portfolio
-
Morgan Stanley New York, NY9.63MShares$273 Million0.02% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$165 Million0.01% of portfolio
-
State Street Corp Boston, MA4.53MShares$128 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.27MShares$121 Million6.01% of portfolio
-
Octagon Capital Advisors LP New York, NY3.01MShares$85.4 Million21.39% of portfolio
-
Siren, L.L.C. New York, NY2.82MShares$80 Million3.97% of portfolio
Latest Institutional Activity in APLS
Top Purchases
Top Sells
About APLS
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Insider Transactions at APLS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 11
2025
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
363
-0.43%
|
$10,164
$28.54 P/Share
|
Jan 29
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
695
-0.48%
|
$20,155
$29.52 P/Share
|
Jan 29
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
546
-0.42%
|
$15,834
$29.52 P/Share
|
Jan 29
2025
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
695
-0.82%
|
$20,155
$29.52 P/Share
|
Jan 29
2025
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
278
-0.5%
|
$8,062
$29.52 P/Share
|
Jan 29
2025
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
364
-0.52%
|
$10,556
$29.52 P/Share
|
Jan 29
2025
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
825
-0.98%
|
$23,925
$29.52 P/Share
|
Jan 29
2025
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
826
-0.07%
|
$23,954
$29.52 P/Share
|
Jan 29
2025
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
365
-0.43%
|
$10,585
$29.52 P/Share
|
Jan 29
2025
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,824
-0.67%
|
$81,896
$29.52 P/Share
|
Jan 22
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
3,323
-2.24%
|
$99,690
$30.43 P/Share
|
Jan 22
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,088
-2.33%
|
$92,640
$30.43 P/Share
|
Jan 22
2025
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,323
-3.77%
|
$99,690
$30.43 P/Share
|
Jan 22
2025
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
3,948
-4.46%
|
$118,440
$30.43 P/Share
|
Jan 22
2025
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,948
-0.34%
|
$118,440
$30.43 P/Share
|
Jan 22
2025
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,291
-2.27%
|
$38,730
$30.43 P/Share
|
Jan 22
2025
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,551
-3.14%
|
$406,530
$30.43 P/Share
|
Jan 22
2025
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,751
-2.42%
|
$52,530
$30.43 P/Share
|
Jan 22
2025
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
1,396
-1.62%
|
$41,880
$30.43 P/Share
|
Jan 22
2025
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,096
-2.23%
|
$32,880
$30.43 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 420K shares |
---|---|
Exercise of conversion of derivative security | 529K shares |
Bona fide gift | 24.7K shares |
Open market or private sale | 690K shares |
---|---|
Bona fide gift | 24.7K shares |
Other acquisition or disposition | 182K shares |